Clark Enterprises-backed Verax Biomedical Raises over Half of $5 Million Mixed Offering
Verax Biomedical Inc., which has developed technology to enable rapid blood tests, has raised $2.78 million, or over 55 percent of a mixed offering of $5 million, from 11 investors, according to an SEC filing.
Principals named in the filing by the Worcester, Mass.-based firm are the following executives:
· CEO James Lousararian;
· Joe Sanders, senior vice president for Marketing and Business Development;
· Nancy Hornbaker, vice president for Regulatory Affairs;
· R. Scott McKenzie, senior vice president of Operations; and
· Greg Lawrence, vice president for Research and Development.
Also named in the filing were the following directors;
· Buzz Benson of Minneapolis-based SightLine Partners;
· Joe Del Guercio of Bethesda, Md.-based Clark Enterprises Inc.;
· Marc Goldberg of Boston-based Bioventures Investors;
· James Koziarz of Midwest Venture Partners; and
· Robert Zieserl of Highland Park, Ill.-based KB Partners.
Lousararian, who began consulting with Verax in the fall of 2005, was named the CEO in February 2006. Prior to joining Verax, he was a consultant for Medtronic Vascular, following that company’s acquisition of Angiolink Corp. in November 2004. Lousararian previously co-founded and led a life sciences startup, AngioLink.
Verax Biomedical enables rapid tests to detect bacterial contaminants in blood components, tissues for transplantation and cellular therapies.